Felix Hernandez

List of Publications by Year in Descending Order

183 papers	8,858 citations	49 h-index	91 g-index
189 ext. papers	9,946 ext. citations	5.9 avg, IF	6.03 L-index

#	Paper	IF	Citations
183	Microtubule-associated protein tau in murine kidney: role in podocyte architecture.. *Cellular and Molecular Life Sciences*, **2022**, 79, 97	10.3	1
182	p38 Inhibition Decreases Tau Toxicity in Microglia and Improves Their Phagocytic Function.. *Molecular Neurobiology*, **2022**, 59, 1632	6.2	1
181	TNAP upregulation is a critical factor in Tauopathies and its blockade ameliorates neurotoxicity and increases life-expectancy.. *Neurobiology of Disease*, **2022**, 165, 105632	7.5	0
180	p38 activation occurs mainly in microglia in the P301S Tauopathy mouse model.. *Scientific Reports*, **2022**, 12, 2130	4.9	0
179	A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease. *Acta Neuropathologica*, **2021**, 142, 159-177	14.3	3
178	Glycolysis and gluconeogenesis: A teaching view. *Journal of Biological Chemistry*, **2021**, 296, 100016	5.4	0
177	CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease. *Science Translational Medicine*, **2021**, 13, eabe7104	17.5	0
176	Focal cerebral ischemia induces changes in oligodendrocytic tau isoforms in the damaged area. *Glia*, **2020**, 68, 2471-2485	9	5
175	Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized With DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins. *Vaccines*, **2020**, 8,	5.3	4
174	ACE2 is on the X chromosome: could this explain COVID-19 gender differences?. *European Heart Journal*, **2020**, 41, 3095	9.5	17
173	Differences Between Human and Murine Tau at the N-terminal End. *Frontiers in Aging Neuroscience*, **2020**, 12, 11	5.3	11
172	Overexpression of GSK-3 In Adult Tet-OFF GSK-3 Transgenic Mice, and Not During Embryonic or Postnatal Development, Induces Tau Phosphorylation, Neurodegeneration and Learning Deficits. *Frontiers in Molecular Neuroscience*, **2020**, 13, 561470	6.1	3
171	In Vivo Reprogramming Ameliorates Aging Features in Dentate Gyrus Cells and Improves Memory in Mice. *Stem Cell Reports*, **2020**, 15, 1056-1066	8	18
170	Tau Protein as a New Regulator of Cellular Prion Protein Transcription. *Molecular Neurobiology*, **2020**, 57, 4170-4186	6.2	2
169	Protein Biomarkers for the Diagnosis of Alzheimer's Disease at Different Stages of Neurodegeneration. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
168	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. *Frontiers in Immunology*, **2020**, 11, 456	8.4	87
167	Role of tau N-terminal motif in the secretion of human tau by End Binding proteins. *PLoS ONE*, **2019**, 14, e0210864	3.7	20

166	Peripheral nervous system effects in the PS19 tau transgenic mouse model of tauopathy. *Neuroscience Letters*, **2019**, 698, 204-208	3.3	4
165	GSK3β overexpression driven by GFAP promoter improves rotarod performance. *Brain Research*, **2019**, 1712, 47-54	3.7	4
164	Extracellular Monomeric Tau Is Internalized by Astrocytes. *Frontiers in Neuroscience*, **2019**, 13, 442	5.1	52
163	Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. *Journal of Alzheimer's Disease*, **2019**, 69, 615-629	4.3	28
162	Phospho-Tau Changes in the Human CA1 During Alzheimer's Disease Progression. *Journal of Alzheimer's Disease*, **2019**, 69, 277-288	4.3	14
161	Differences in structure and function between human and murine tau. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2019**, 1865, 2024-2030	6.9	10
160	Propagation of Tau via Extracellular Vesicles. *Frontiers in Neuroscience*, **2019**, 13, 698	5.1	43
159	Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer's disease. *Scientific Reports*, **2019**, 9, 15437	4.9	37
158	New Beginnings in Alzheimer's Disease: The Most Prevalent Tauopathy. *Journal of Alzheimer's Disease*, **2018**, 64, S529-S534	4.3	4
157	Frontotemporal Dementia-Associated N279K Tau Mutation Localizes at the Nuclear Compartment. *Frontiers in Cellular Neuroscience*, **2018**, 12, 202	6.1	4
156	Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	28
155	Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17. *International Journal of Physiology, Pathophysiology and Pharmacology*, **2018**, 10, 172-183	2.4	2
154	Human Brain Single Nucleotide Polymorphism: Validation of DNA Sequencing. *Journal of Alzheimer's Disease Reports*, **2018**, 2, 103-109	3.3	1
153	MicroRNA-22 Controls Aberrant Neurogenesis and Changes in Neuronal Morphology After Status Epilepticus. *Frontiers in Molecular Neuroscience*, **2018**, 11, 442	6.1	13
152	Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus. *Cell Death and Disease*, **2018**, 9, 969	9.8	16
151	Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro. *Biomolecular Concepts*, **2018**, 9, 1-11	3.7	9
150	Tau-positive nuclear indentations in P301S tauopathy mice. *Brain Pathology*, **2017**, 27, 314-322	6	9
149	Validation of Suspected Somatic Single Nucleotide Variations in the Brain of Alzheimer's Disease Patients. *Journal of Alzheimer's Disease*, **2017**, 56, 977-990	4.3	6

148	Mass spectrometric identification and structural analysis of the third-generation synthetic cannabinoids on the UK market since the 2013 legislative ban. *Forensic Toxicology*, **2017**, 35, 376-388	2.6	14
147	Phospho-Tau Accumulation and Structural Alterations of the Golgi Apparatus of Cortical Pyramidal Neurons in the P301S Tauopathy Mouse Model. *Journal of Alzheimer's Disease*, **2017**, 60, 651-661	4.3	6
146	Absence of CX3CR1 impairs the internalization of Tau by microglia. *Molecular Neurodegeneration*, **2017**, 12, 59	19	90
145	Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer's disease. *Cellular and Molecular Life Sciences*, **2017**, 74, 1153-1163	10.3	8
144	Excitotoxic inactivation of constitutive oxidative stress detoxification pathway in neurons can be rescued by PKD1. *Nature Communications*, **2017**, 8, 2275	17.4	11
143	Cognitive Decline in Neuronal Aging and Alzheimer's Disease: Role of NMDA Receptors and Associated Proteins. *Frontiers in Neuroscience*, **2017**, 11, 626	5.1	27
142	Commentary: Genome-wide association study identifies 74 loci associated with educational attainment. *Frontiers in Molecular Neuroscience*, **2017**, 10, 23	6.1	3
141	Decreased adult neurogenesis in hibernating Syrian hamster. *Neuroscience*, **2016**, 333, 181-92	3.9	18
140	A Simple Model to Study Tau Pathology. *Journal of Experimental Neuroscience*, **2016**, 10, 31-8	3.6	18
139	GSK3β Overexpression in Dentate Gyrus Neural Precursor Cells Expands the Progenitor Pool and Enhances Memory Skills. *Journal of Biological Chemistry*, **2016**, 291, 8199-213	5.4	17
138	Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 653-61	6.4	19
137	Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo. *Journal of Alzheimer's Disease*, **2016**, 50, 77-87	4.3	113
136	Tau Structures. *Frontiers in Aging Neuroscience*, **2016**, 8, 262	5.3	55
135	New Features about Tau Function and Dysfunction. *Biomolecules*, **2016**, 6,	5.9	54
134	Novel function of Tau in regulating the effects of external stimuli on adult hippocampal neurogenesis. *EMBO Journal*, **2016**, 35, 1417-36	13	56
133	Secretion of full-length tau or tau fragments in a cell culture model. *Neuroscience Letters*, **2016**, 634, 63-69	3.3	17
132	Excitotoxicity induced by kainic acid provokes glycogen synthase kinase-3 truncation in the hippocampus. *Brain Research*, **2015**, 1611, 84-92	3.7	3
131	Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. *Human Molecular Genetics*, **2015**, 24, 5040-52	5.6	27

130	TNAP Plays a Key Role in Neural Differentiation as well as in Neurodegenerative Disorders. *Sub-Cellular Biochemistry*, **2015**, 76, 375-85	5.5	8
129	Novel connection between newborn granule neurons and the hippocampal CA2 field. *Experimental Neurology*, **2015**, 263, 285-92	5.7	43
128	Alternative neural circuitry that might be impaired in the development of Alzheimer disease. *Frontiers in Neuroscience*, **2015**, 9, 145	5.1	5
127	Huntington's disease is a four-repeat tauopathy with tau nuclear rods. *Nature Medicine*, **2014**, 20, 881-5	50.5	135
126	Tau triggers tear secretion by interacting with muscarinic acetylcholine receptors in New Zealand white rabbits. *Journal of Alzheimer's Disease*, **2014**, 40 Suppl 1, S71-7	4.3	2
125	Sources of extracellular tau and its signaling. *Journal of Alzheimer's Disease*, **2014**, 40 Suppl 1, S7-S15	4.3	22
124	GSK-3β a pivotal kinase in Alzheimer disease. *Frontiers in Molecular Neuroscience*, **2014**, 7, 46	6.1	285
123	Boronate-tau mediated uptake in neurons. *Journal of Alzheimer's Disease*, **2014**, 40, 143-51	4.3	
122	Thermodynamics of the interaction between Alzheimer's disease related tau protein and DNA. *PLoS ONE*, **2014**, 9, e104690	3.7	29
121	Selective alterations of neurons and circuits related to early memory loss in Alzheimer's disease. *Frontiers in Neuroanatomy*, **2014**, 8, 38	3.6	55
120	Argyrophilic grain pathology as a natural model of tau propagation. *Journal of Alzheimer's Disease*, **2014**, 40 Suppl 1, S123-33	4.3	12
119	B24 Huntington's Disease As A Tauopathy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, A17-A17	5.5	
118	Peripherally triggered and GSK-3β-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen. *Translational Psychiatry*, **2014**, 4, e463	8.6	38
117	Kidins220 accumulates with tau in human Alzheimer's disease and related models: modulation of its calpain-processing by GSK3β/PP1 imbalance. *Human Molecular Genetics*, **2013**, 22, 466-82	5.6	22
116	GSK-3β overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. *Molecular Psychiatry*, **2013**, 18, 451-60	15.1	90
115	GSK3 and tau: two convergence points in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2013**, 33 Suppl 1, S141-4	4.3	162
114	Alzheimer disease-like cellular phenotype of newborn granule neurons can be reversed in GSK-3β overexpressing mice. *Molecular Psychiatry*, **2013**, 18, 395	15.1	6
113	Changes in tau phosphorylation in hibernating rodents. *Journal of Neuroscience Research*, **2013**, 91, 954-62	4.4	16

112	Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. *Mediators of Inflammation*, **2013**, 2013, 260925	4.3	97
111	Dual effects of increased glycogen synthase kinase-3β activity on adult neurogenesis. *Human Molecular Genetics*, **2013**, 22, 1300-15	5.6	41
110	The involvement of cholinergic neurons in the spreading of tau pathology. *Frontiers in Neurology*, **2013**, 4, 74	4.1	15
109	Specific profile of tau isoforms in argyrophylic grain disease. *Journal of Experimental Neuroscience*, **2013**, 7, 51-9	3.6	3
108	Microtubule depolymerization and tau phosphorylation. *Journal of Alzheimer's Disease*, **2013**, 37, 507-13	4.3	15
107	Tau and neuron aging **2013**, 4, 23-8		8
106	Tau Phosphorylation by GSK3 in Different Conditions. *International Journal of Alzheimer's Disease*, **2012**, 2012, 578373	3.7	57
105	Tau protein and adult hippocampal neurogenesis. *Frontiers in Neuroscience*, **2012**, 6, 104	5.1	48
104	Looking for novel functions of tau. *Biochemical Society Transactions*, **2012**, 40, 653-5	5.1	15
103	Tau overexpression results in its secretion via membrane vesicles. *Neurodegenerative Diseases*, **2012**, 10, 73-5	2.3	61
102	Tau isoform with three microtubule binding domains is a marker of new axons generated from the subgranular zone in the hippocampal dentate gyrus: implications for Alzheimer's disease. *Journal of Alzheimer's Disease*, **2012**, 29, 921-30	4.3	27
101	Tau Phosphorylation. *Advances in Neurobiology*, **2011**, 73-82	2.1	2
100	Calpain regulates N-terminal interaction of GSK-3β with 14-3-3β, p53 and PKB but not with axin. *Neurochemistry International*, **2011**, 59, 97-100	4.4	11
99	Expression of frontotemporal dementia with parkinsonism associated to chromosome 17 tau induces specific degeneration of the ventral dentate gyrus and depressive-like behavior in mice. *Neuroscience*, **2011**, 196, 215-27	3.9	12
98	Different susceptibility to neurodegeneration of dorsal and ventral hippocampal dentate gyrus: a study with transgenic mice overexpressing GSK3β. *PLoS ONE*, **2011**, 6, e27262	3.7	24
97	GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. *Frontiers in Molecular Neuroscience*, **2011**, 4, 45	6.1	49
96	GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. *Hippocampus*, **2011**, 21, 910-22	3.5	61
95	Neuronal models for studying tau pathology. *International Journal of Alzheimer's Disease*, **2010**, 2010,	3.7	1

94	Centro de Biologia Molecular "Severo Ochoa": a center for basic research into Alzheimer's disease. *Journal of Alzheimer's Disease*, **2010**, 21, 325-35	4.3	
93	Tau kinase I overexpression induces dentate gyrus degeneration. *Neurodegenerative Diseases*, **2010**, 7, 13-5	2.3	4
92	Intra- and extracellular protein interactions with tau. *Current Alzheimer Research*, **2010**, 7, 670-6	3	9
91	Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. *Journal of Neuroscience*, **2010**, 30, 3675-88	6.6	76
90	GSK3: a possible link between beta amyloid peptide and tau protein. *Experimental Neurology*, **2010**, 223, 322-5	5.7	200
89	Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. *Expert Review of Neurotherapeutics*, **2010**, 10, 703-10	4.3	90
88	Tau phosphorylation in hippocampus results in toxic gain-of-function. *Biochemical Society Transactions*, **2010**, 38, 977-80	5.1	21
87	Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. *Molecular and Cellular Biochemistry*, **2010**, 344, 211-5	4.2	68
86	Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. *Neurobiology of Disease*, **2010**, 37, 622-9	7.5	87
85	GSK3 inhibitors and disease. *Mini-Reviews in Medicinal Chemistry*, **2009**, 9, 1024-9	3.2	37
84	Function of tau protein in adult newborn neurons. *FEBS Letters*, **2009**, 583, 3063-8	3.8	41
83	Calpain-mediated truncation of GSK-3 in post-mortem brain samples. *Journal of Neuroscience Research*, **2009**, 87, 1156-61	4.4	15
82	The role of GSK3 in Alzheimer disease. *Brain Research Bulletin*, **2009**, 80, 248-50	3.9	59
81	Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2009**, 18, 843-8	4.3	15
80	The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. *FEBS Letters*, **2008**, 582, 3848-54	3.8	61
79	Hippocampal neuronal subpopulations are differentially affected in double transgenic mice overexpressing frontotemporal dementia and parkinsonism linked to chromosome 17 tau and glycogen synthase kinase-3beta. *Neuroscience*, **2008**, 157, 772-80	3.9	8
78	Induction of paclitaxel resistance by the Kaposi's sarcoma-associated herpesvirus latent protein LANA2. *Journal of Virology*, **2008**, 82, 1518-25	6.6	18
77	Lithium, a potential protective drug in Alzheimer's disease. *Neurodegenerative Diseases*, **2008**, 5, 247-9	2.3	37

76	Binding of tau protein to the ends of ex vivo paired helical filaments. *Journal of Alzheimer's Disease*, **2008**, 13, 177-85	4.3	1
75	Coenzyme q induces tau aggregation, tau filaments, and Hirano bodies. *Journal of Neuropathology and Experimental Neurology*, **2008**, 67, 428-34	3.1	10
74	Tau as a molecular marker of development, aging and neurodegenerative disorders. *Current Aging Science*, **2008**, 1, 56-61	2.2	12
73	Tau aggregates and tau pathology. *Journal of Alzheimer's Disease*, **2008**, 14, 449-52	4.3	36
72	Co-expression of FTDP-17 Human Tau and GSK-3β (or APPSW) in Transgenic Mice: Induction of Tau Polymerization and Neurodegeneration **2008**, 337-342		
71	Role of polyglycine repeats in the regulation of glycogen synthase kinase activity. *Protein and Peptide Letters*, **2008**, 15, 586-9	1.9	1
70	A mouse model to study tau pathology related with tau phosphorylation and assembly. *Journal of the Neurological Sciences*, **2007**, 257, 250-4	3.2	7
69	Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. *Molecular Neurodegeneration*, **2007**, 2, 17	19	54
68	Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. *EMBO Journal*, **2007**, 26, 2743-54	13	54
67	Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. *European Journal of Neuroscience*, **2007**, 25, 81-6	3.5	268
66	The role of the VQIVYK peptide in tau protein phosphorylation. *Journal of Neurochemistry*, **2007**, 103, 1447-60	6	19
65	Tauopathies. *Cellular and Molecular Life Sciences*, **2007**, 64, 2219-33	10.3	226
64	N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. *Journal of Biological Chemistry*, **2007**, 282, 22406-13	5.4	99
63	Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin. *Brain Research Bulletin*, **2007**, 72, 121-3	3.9	6
62	Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. *Neuroscience Letters*, **2007**, 429, 91-4	3.3	44
61	GSK-3 inhibitors for Alzheimer's disease. *Expert Review of Neurotherapeutics*, **2007**, 7, 1527-33	4.3	64
60	Tau phosphorylation, aggregation, and cell toxicity. *Journal of Biomedicine and Biotechnology*, **2006**, 2006, 74539		35
59	Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. *Journal of Biological Chemistry*, **2006**, 281, 16591-8	5.4	167

58	Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. *Journal of Neuroscience*, **2006**, 26, 5083-90	6.6	217
57	Extracellular tau is toxic to neuronal cells. *FEBS Letters*, **2006**, 580, 4842-50	3.8	169
56	In vitro tau fibrillization: mapping protein regions. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2006**, 1762, 683-92	6.9	16
55	Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. *Neurobiology of Aging*, **2006**, 27, 1258-68	5.6	96
54	Characteristics of the binding of thioflavin S to tau paired helical filaments. *Journal of Alzheimer's Disease*, **2006**, 9, 279-85	4.3	35
53	Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. *Journal of Neurochemistry*, **2006**, 98, 1585-96	6	77
52	Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. *Journal of Neurochemistry*, **2006**, 99, 1445-55	6	169
51	Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2005**, 1740, 472-80	6.9	36
50	Phosphorylation modulates the alpha-helical structure and polymerization of a peptide from the third tau microtubule-binding repeat. *Biochimica Et Biophysica Acta - General Subjects*, **2005**, 1721, 16-26	4	20
49	Characterization of Alzheimer paired helical filaments by electron microscopy. *Microscopy Research and Technique*, **2005**, 67, 121-5	2.8	5
48	Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers. *Molecular and Cellular Biochemistry*, **2005**, 278, 203-12	4.2	28
47	The ubiquitin-proteasome system in Huntington's disease. *Neuroscientist*, **2005**, 11, 583-94	7.6	42
46	Assembly in vitro of tau protein and its implications in Alzheimer's disease. *Current Alzheimer Research*, **2004**, 1, 97-101	3	21
45	Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. *Journal of Neuroscience*, **2004**, 24, 9361-71	6.6	47
44	Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. *Journal of Biological Chemistry*, **2004**, 279, 3801-6	5.4	103
43	Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. *Neurotoxicity Research*, **2004**, 6, 463-8	4.3	36
42	Tau in neurodegenerative diseases: tau phosphorylation and assembly. *Neurotoxicity Research*, **2004**, 6, 477-82	4.3	39
41	Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. *Biochemistry*, **2004**, 43, 2888-97	3.2	49

40	Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. *Trends in Neurosciences*, **2004**, 27, 66-9	13.3	33
39	M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. *Neurobiology of Disease*, **2004**, 17, 337-48	7.5	68
38	Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. *Neuroscience Letters*, **2004**, 357, 143-6	3.3	53
37	Role of tau protein in both physiological and pathological conditions. *Physiological Reviews*, **2004**, 84, 361-84	47.9	641
36	Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. *Journal of Alzheimer's Disease*, **2003**, 5, 301-8	4.3	159
35	Neuronal induction of the immunoproteasome in Huntington's disease. *Journal of Neuroscience*, **2003**, 23, 11653-61	6.6	218
34	GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. *Neurobiology of Aging*, **2003**, 24, 1087-94	5.6	36
33	Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. *Journal of Biological Chemistry*, **2003**, 278, 45937-45	5.4	393
32	Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2002**, 2, 51-8	3.2	8
31	Sulfo-glycosaminoglycan content affects PHF-tau solubility and allows the identification of different types of PHFs. *Brain Research*, **2002**, 935, 65-72	3.7	17
30	Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. *Journal of Neurochemistry*, **2002**, 83, 1529-33	6	291
29	Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. *FEBS Journal*, **2002**, 269, 1484-9		76
28	Alpha-helix structure in Alzheimer's disease aggregates of tau-protein. *Biochemistry*, **2002**, 41, 7150-5	3.2	100
27	Phosphorylation, Microtubule Binding and Aggregation of Tau Protein in Alzheimer's Disease **2001**, 601-607		
26	Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. *EMBO Journal*, **2001**, 20, 27-39	13	670
25	FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. *Molecular and Cellular Neurosciences*, **2001**, 18, 702-14	4.8	176
24	Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. *Journal of Neuroscience*, **2001**, 21, 8772-81	6.6	136
23	Endothelin inhibits histamine-induced cyclic AMP accumulation in bovine brain vessels. *Microvascular Research*, **2000**, 60, 49-54	3.7	4

22	Endothelin-1 increases isoprenaline-enhanced cyclic AMP levels in cerebral cortex. *Regulatory Peptides*, **2000**, 88, 41-6		4
21	Endothelin enhances adenosine and isoprenaline elevated cyclic AMP levels in rat cerebellar slices. *Peptides*, **1999**, 20, 1115-22	3.8	2
20	Nuclear localization of beta-catenin in adult mouse thalamus correlates with low levels of GSK-3beta. *NeuroReport*, **1999**, 10, 2699-703	1.7	12
19	Heterogeneity of beta-adrenoceptors in guinea-pig brain: radioligand binding and cyclic nucleotide generation. *Journal of Neurochemistry*, **1997**, 68, 2610-7	6	3
18	Identification of nitric oxide synthases in isolated bovine brain vessels. *Neuroscience Research*, **1996** , 25, 195-9	2.9	17
17	Protein phosphorylation in the blood-brain barrier. Possible presence of MARCKS in brain microvessels. *Neurochemistry International*, **1996**, 28, 59-65	4.4	1
16	Endothelin stimulates protein phosphorylation in blood-brain barrier. *Biochemical and Biophysical Research Communications*, **1996**, 219, 366-9	3.4	8
15	Nitric oxide mediates the PAF-stimulated cyclic GMP production in hippocampal slices. *Biochemical and Biophysical Research Communications*, **1996**, 226, 27-31	3.4	3
14	Regulation of phosphoinositide cycle by intracellular sodium in the blood-brain barrier. *Cellular Signalling*, **1996**, 8, 387-92	4.9	3
13	Further studies on the mechanism of action of substance P in rat brain, involving selective phosphatidylinositol hydrolysis. *Neurochemical Research*, **1995**, 20, 1147-53	4.6	4
12	Involvement of calcium in phosphoinositide metabolism in the blood-brain barrier. *Cellular Signalling*, **1995**, 7, 261-7	4.9	4
11	Endothelin-1 stimulates myristoylated alanine-rich C-kinase substrate (MARCKS) phosphorylation in rat cerebellar slices. *Neuroscience Letters*, **1995**, 194, 53-6	3.3	4
10	Forskolin and 3-isobutyl-1-methylxanthine increase basal and sodium nitroprusside-elevated cyclic GMP levels in adult guinea-pig cerebellar slices. *Journal of Neurochemistry*, **1994**, 62, 2212-8	6	12
9	Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. *Thrombosis Research*, **1994**, 75, 121-32	8.2	3
8	Natriuretic peptide-induced cyclic GMP accumulation in adult guinea-pig cerebellar slices. *British Journal of Pharmacology*, **1994**, 113, 216-20	8.6	6
7	Tetrahydroaminoacridine affects the cholinergic function of blood-brain barrier. *Life Sciences*, **1993**, 53, 1165-72	6.8	3
6	Adenosine receptor-induced second messenger production in adult guinea-pig cerebellum. *British Journal of Pharmacology*, **1993**, 110, 1085-90	8.6	13
5	Molecular forms of butyrylcholinesterase in rat brain microvessels. *Neuroscience Letters*, **1990**, 120, 46-9	3.3	10

4	Dual mechanism of phosphatidylinositol hydrolysis by substance P in brain. *FEBS Journal*, **1988**, 172, 547-52		12
3	Temperature effects on cholinesterases from rat brain capillaries. *Bioscience Reports*, **1986**, 6, 573-7	4.1	4
2	GSK-3, a Key Player in Alzheimer's Disease105-124		
1	Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies203-219		